Experiment 67530
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | COYLE,J: KERSHAW,P:. (2001). GALANTAMINE, A CHOLINESTERASE INHIBITOR THAT ALLOSTERICALLY MODULATES NICOTINIC RECEPTORS: EFFECTS ON THE COURSE OF ALZHEIMER'S DISEASE.. 49(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF UP TO 6 MONTHS DURATION, GALANTAMINE SIGNIFICANTLY IMPROVED COGNITIVE FUNCTION. GALANTAMINE ALSO HAD BENEFICAL EFFECTS ON INSTRUMENTAL AND BASIC ACTIVITIES OF DAILY LIVING, AND POSTPONED THE PROGRESSION OF BEHAVIORAL SYMPTOMS. PATIENTS WHO COMPLETED ONE OF THE 6-MONTH, PLACEBO-CONTROLLED STUDIES WERE ELIGIBLE TO ENTER A 6-MONTH, OPEN-EXTENSION STUDY OF THE 24-MG/DAY DOSE OF GALANTAMINE. AT THE END OF 12 MONTHS, COGNITIVE FUNCTION AND ACTIVITIES OF DAILY LIVING WERE PRESERVED IN THOSE PATIENTS WHO HAD BEEN TREATED THROUGHTOUT THE STUDY WITH GALANTAMINE 24 MG/DAY. AT 12 MONTHS, THIS GROUP OF PATIENTS HAD SIGNIFICANTLY BETTER COGNITIVE FUNCTIONS THAN PATIENTS WHO HAD BEEN TREATED WITH A PLACEBO FOR 6 MONTHS BEFORE RECEIVING GALANTAMINE. |
| Dose amount | VAR |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |